Pfizer Inc. said on Thursday that its experimental antibiotic combination can treat some superbug infections, including those caused by the drug-resistant bacteria carbapenem-resistant Enterobacteriaceae (CRE).
The company said the combination, which consists of two existing antibiotics, ceftolozane and tazobactam, was effective in treating patients with CRE infections who had failed other treatments.
The news comes as the world faces a growing threat from antibiotic resistance. CRE infections are particularly difficult to treat because they are resistant to many common antibiotics.
Pfizer's combination is the first new antibiotic to be approved for the treatment of CRE infections in more than a decade. The company said it plans to file for regulatory approval in the United States and Europe later this year.
"This is a significant advance in the fight against antibiotic resistance," said Mikael Dolsten, Pfizer's chief scientific officer. "This new treatment option could help patients who have no other options."
The approval of Pfizer's combination is a major victory for the global effort to combat antibiotic resistance. However, it is important to note that the combination is not a cure for antibiotic resistance. It is simply one more tool in the fight against this growing threat.
Analysis
Pfizer's announcement is a major breakthrough in the fight against antibiotic resistance. The company's experimental antibiotic combination is the first new treatment for CRE infections in more than a decade.
CRE infections are particularly difficult to treat because they are resistant to many common antibiotics. This makes them a major threat to public health.
Pfizer's combination is a combination of two existing antibiotics, ceftolozane and tazobactam. The company said the combination was effective in treating patients with CRE infections who had failed other treatments.
The approval of Pfizer's combination is a major victory for the global effort to combat antibiotic resistance. However, it is important to note that the combination is not a cure for antibiotic resistance. It is simply one more tool in the fight against this growing threat.
The development of new antibiotics is essential to the fight against antibiotic resistance. However, it is a complex and challenging process. It can take many years and billions of dollars to develop a new antibiotic.
Pfizer's announcement is a sign of hope in the fight against antibiotic resistance. However, it is important to remember that the battle is far from over. We need to continue to invest in research and development of new antibiotics if we are to protect ourselves from this growing threat.
People also ask
⚐ What are the top stocks to invest in right now?☵ What happens to stocks when they're delisted?